{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,25]],"date-time":"2026-10-25T00:07:42Z","timestamp":1792886862390,"version":"4.5.0"},"reference-count":77,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2020,10,20]],"date-time":"2020-10-20T00:00:00Z","timestamp":1603152000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,10,20]],"date-time":"2020-10-20T00:00:00Z","timestamp":1603152000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Hypertens Rep"],"published-print":{"date-parts":[[2020,11]]},"DOI":"10.1007\/s11906-020-01108-3","type":"journal-article","created":{"date-parts":[[2020,10,20]],"date-time":"2020-10-20T04:04:01Z","timestamp":1603166641000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":31,"title":["Endocrine Causes of Hypertension"],"prefix":"10.1007","volume":"22","author":[{"given":"Taniya","family":"de Silva","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gina","family":"Cosentino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suneeta","family":"Ganji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alejandra","family":"Riera-Gonzalez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel S.","family":"Hsia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,10,20]]},"reference":[{"issue":"6","key":"1108_CR1","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1161\/CIRCULATIONAHA.115.018912","volume":"134","author":"KT Mills","year":"2016","unstructured":"Mills KT, Bundy JD, Kelly TN, Reed JE, Kearney PM, Reynolds K, et al. Global disparities of hypertension prevalence and control: a systematic analysis of population-based studies from 90 countries. Circulation. 2016;134(6):441\u201350.","journal-title":"Circulation"},{"issue":"7","key":"1108_CR2","first-page":"453","volume":"96","author":"L Charles","year":"2017","unstructured":"Charles L, Triscott J, Dobbs B. Secondary hypertension: discovering the underlying cause. Am Fam Physician. 2017;96(7):453\u201361.","journal-title":"Am Fam Physician"},{"issue":"2","key":"1108_CR3","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1210\/er.2017-00054","volume":"38","author":"WF Young Jr","year":"2017","unstructured":"Young WF Jr, Calhoun DA, Lenders JWM, Stowasser M, Textor SC. Screening for endocrine hypertension: an endocrine society scientific statement. Endocr Rev. 2017;38(2):103\u201322.","journal-title":"Endocr Rev"},{"issue":"2","key":"1108_CR4","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1111\/joim.12831","volume":"285","author":"WF Young Jr","year":"2019","unstructured":"Young WF Jr. Diagnosis and treatment of primary aldosteronism: practical clinical perspectives. J Intern Med. 2019;285(2):126\u201348.","journal-title":"J Intern Med"},{"issue":"1","key":"1108_CR5","doi-asserted-by":"crossref","first-page":"45","DOI":"10.3109\/00365513.2015.1092047","volume":"76","author":"M Pedersen","year":"2016","unstructured":"Pedersen M, Karlsen MA, Ankj\u00e6rgaard KL, Jensen LT. Primary hyperaldosteronism diagnosed with adrenal vein sampling. Characteristics and follow-up after adrenalectomy in a Danish study. Scand J Clin Lab Invest. 2016;76(1):45\u201350.","journal-title":"Scand J Clin Lab Invest"},{"issue":"4","key":"1108_CR6","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1016\/j.suc.2019.04.010","volume":"99","author":"FT Lee","year":"2019","unstructured":"Lee FT, Elaraj D. Evaluation and management of primary hyperaldosteronism. Surg Clin North Am. 2019;99(4):731\u201345.","journal-title":"Surg Clin North Am"},{"issue":"5","key":"1108_CR7","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1210\/jc.2015-4061","volume":"101","author":"JW Funder","year":"2016","unstructured":"Funder JW, Carey RM, Mantero F, Murad MH, Reincke M, Shibata H, et al. The management of primary aldosteronism: case detection, diagnosis, and treatment: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2016;101(5):1889\u2013916.","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"1108_CR8","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1016\/j.surg.2017.10.012","volume":"163","author":"V Strajina","year":"2018","unstructured":"Strajina V, al-Hilli Z, Andrews JC, Bancos I, Thompson GB, Farley DR, et al. Primary aldosteronism: making sense of partial data sets from failed adrenal venous sampling-suppression of adrenal aldosterone production can be used in clinical decision making. Surgery. 2018;163(4):801\u20136.","journal-title":"Surgery"},{"issue":"9","key":"1108_CR9","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1016\/S2213-8587(17)30135-3","volume":"5","author":"TA Williams","year":"2017","unstructured":"Williams TA, Lenders JWM, Mulatero P, Burrello J, Rottenkolber M, Adolf C, et al. Outcomes after adrenalectomy for unilateral primary aldosteronism: an international consensus on outcome measures and analysis of remission rates in an international cohort. Lancet Diabetes Endocrinol. 2017;5(9):689\u201399.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"1","key":"1108_CR10","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/S2213-8587(17)30367-4","volume":"6","author":"GL Hundemer","year":"2018","unstructured":"\u2022\u2022 Hundemer GL, et al. Cardiometabolic outcomes and mortality in medically treated primary aldosteronism: a retrospective cohort study. Lancet Diabetes Endocrinol. 2018;6(1):51\u20139 This article is very significant as it offers data to support a novel recommendation for titration of mineralocorticoid receptor blockers to achieve unsuppressed renin levels to optimize cardiometabolic outcomes in patients with primary aldosteronism.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"6","key":"1108_CR11","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1056\/NEJMra1806651","volume":"381","author":"HPH Neumann","year":"2019","unstructured":"Neumann HPH, Young WF Jr, Eng C. Pheochromocytoma and Paraganglioma. N Engl J Med. 2019;381(6):552\u201365.","journal-title":"N Engl J Med"},{"issue":"5","key":"1108_CR12","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1210\/jc.2018-01707","volume":"104","author":"LM Gruber","year":"2019","unstructured":"Gruber LM, Hartman RP, Thompson GB, McKenzie TJ, Lyden ML, Dy BM, et al. Pheochromocytoma characteristics and behavior differ depending on method of discovery. J Clin Endocrinol Metab. 2019;104(5):1386\u201393.","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"1108_CR13","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1210\/jc.2018-01532","volume":"104","author":"L Canu","year":"2019","unstructured":"\u2022 Canu L, et al. CT characteristics of pheochromocytoma: relevance for the evaluation of adrenal incidentaloma. J Clin Endocrinol Metab. 2019;104(2):312\u20138 This article is noteworthy as it offers data to support recommendations regarding best imaging modalities and algorithms to distinguish pheochromocytomas from lipid-rich adenomas.","journal-title":"J Clin Endocrinol Metab"},{"key":"1108_CR14","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1111\/cen.14222","volume":"93","author":"NE Kittah","year":"2020","unstructured":"Kittah NE, Gruber LM, Bancos I, Hamidi O, Tamhane S, I\u00f1iguez-Ariza N, et al. Bilateral pheochromocytoma: clinical characteristics, treatment, and longitudinal follow-up. Clin Endocrinol. 2020;93:288\u201395.","journal-title":"Clin Endocrinol"},{"key":"1108_CR15","doi-asserted-by":"crossref","first-page":"3812","DOI":"10.1210\/jc.2018-02355","volume":"104","author":"D Rao","year":"2019","unstructured":"Rao D, van Berkel A, Piscaer I, Young WF, Gruber L, Deutschbein T, et al. Impact of 123 I-MIBG scintigraphy on clinical decision making in pheochromocytoma and paraganglioma. J Clin Endocrinol Metab. 2019;104:3812\u201320.","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"1108_CR16","doi-asserted-by":"crossref","first-page":"362","DOI":"10.21037\/gs.2020.03.04","volume":"9","author":"LM Gruber","year":"2020","unstructured":"Gruber LM, Strajina V, Bancos I, Murad MH, Dy BM, Young WF, et al. Not all adrenal incidentalomas require biochemical testing to exclude pheochromocytoma: Mayo clinic experience and a meta-analysis. Gland Surg. 2020;9(2):362\u201371.","journal-title":"Gland Surg"},{"issue":"6","key":"1108_CR17","doi-asserted-by":"crossref","first-page":"2077","DOI":"10.1210\/jc.2012-1061","volume":"97","author":"T Sane","year":"2012","unstructured":"Sane T, Schalin-Jantti C, Raade M. Is biochemical screening for pheochromocytoma in adrenal incidentalomas expressing low unenhanced attenuation on computed tomography necessary? J Clin Endocrinol Metab. 2012;97(6):2077\u201383.","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"1108_CR18","doi-asserted-by":"crossref","first-page":"481","DOI":"10.3803\/EnM.2015.30.4.481","volume":"30","author":"C Schalin-Jantti","year":"2015","unstructured":"Schalin-Jantti C, et al. A 5-year prospective follow-up study of lipid-rich adrenal incidentalomas: no tumor growth or development of hormonal hypersecretion. Endocrinol Metab (Seoul). 2015;30(4):481\u20137.","journal-title":"Endocrinol Metab (Seoul)"},{"key":"1108_CR19","doi-asserted-by":"crossref","unstructured":"Young WF. Metastatic pheochromocytoma: in search of a cure. Endocrinology. 2020;161(3):1\u20134.","DOI":"10.1210\/endocr\/bqz019"},{"key":"1108_CR20","doi-asserted-by":"crossref","unstructured":"Kohlenberg J, et al. Efficacy and safety of ablative therapy in the treatment of patients with metastatic pheochromocytoma and paraganglioma. Cancers (Basel). 2019;11(2):186\u201398.","DOI":"10.3390\/cancers11020195"},{"issue":"1","key":"1108_CR21","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.adro.2017.11.002","volume":"3","author":"W Breen","year":"2018","unstructured":"Breen W, Bancos I, Young WF Jr, Bible KC, Laack NN, Foote RL, et al. External beam radiation therapy for advanced\/unresectable malignant paraganglioma and pheochromocytoma. Adv Radiat Oncol. 2018;3(1):25\u20139.","journal-title":"Adv Radiat Oncol"},{"issue":"3","key":"1108_CR22","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1007\/s11102-014-0569-6","volume":"18","author":"MS Broder","year":"2015","unstructured":"Broder MS, Neary MP, Chang E, Cherepanov D, Ludlam WH. Incidence of Cushing\u2019s syndrome and Cushing\u2019s disease in commercially-insured patients <65 years old in the United States. Pituitary. 2015;18(3):283\u20139.","journal-title":"Pituitary"},{"key":"1108_CR23","doi-asserted-by":"crossref","first-page":"321","DOI":"10.3389\/fendo.2019.00321","volume":"10","author":"M Barbot","year":"2019","unstructured":"\u2022 Barbot M, Ceccato F, Scaroni C. The pathophysiology and treatment of hypertension in patients with Cushing\u2019s syndrome. Front Endocrinol (Lausanne). 2019;10:321 This is a recent and thorough review of the mechanisms contributing to hypertension in Cushing\u2019s syndrome and evaluates current treatments and their effectiveness for reversing hypertension.","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"5","key":"1108_CR24","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.1210\/jc.2008-0125","volume":"93","author":"LK Nieman","year":"2008","unstructured":"Nieman LK, Biller BMK, Findling JW, Newell-Price J, Savage MO, Stewart PM, et al. The diagnosis of Cushing\u2019s syndrome: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2008;93(5):1526\u201340.","journal-title":"J Clin Endocrinol Metab"},{"issue":"8","key":"1108_CR25","doi-asserted-by":"crossref","first-page":"2807","DOI":"10.1210\/jc.2015-1818","volume":"100","author":"LK Nieman","year":"2015","unstructured":"Nieman LK, Biller BM, Findling JW, Murad MH, Newell-Price J, Savage MO, et al. Treatment of Cushing\u2019s syndrome: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2015;100(8):2807\u201331.","journal-title":"J Clin Endocrinol Metab"},{"issue":"9","key":"1108_CR26","doi-asserted-by":"crossref","first-page":"3231","DOI":"10.1210\/JC.2015-1589","volume":"100","author":"AM Isidori","year":"2015","unstructured":"Isidori AM, Sbardella E, Zatelli MC, Boschetti M, Vitale G, Colao A, et al. Conventional and nuclear medicine imaging in ectopic Cushing\u2019s syndrome: a systematic review. J Clin Endocrinol Metab. 2015;100(9):3231\u201344.","journal-title":"J Clin Endocrinol Metab"},{"key":"1108_CR27","unstructured":"Pirahanchi Y, Tariq MA, Jialal I. Physiology, Thyroid Stimulating Hormone. In: StatPearls. Treasure Island (FL); 2020."},{"key":"1108_CR28","doi-asserted-by":"crossref","first-page":"482","DOI":"10.3389\/fendo.2019.00482","volume":"10","author":"E Berta","year":"2019","unstructured":"\u2022\u2022 Berta E, et al. Hypertension in thyroid disorders. Front Endocrinol (Lausanne). 2019;10:482 This review provides a summary of how thyroid hormone metabolism and functional thyroid diseases impact the cardiovascular system with a focus on hypertension.","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"7","key":"1108_CR29","doi-asserted-by":"crossref","first-page":"2936","DOI":"10.1210\/jc.2012-4223","volume":"98","author":"NC Hadlow","year":"2013","unstructured":"Hadlow NC, Rothacker KM, Wardrop R, Brown SJ, Lim EM, Walsh JP. The relationship between TSH and free T(4) in a large population is complex and nonlinear and differs by age and sex. J Clin Endocrinol Metab. 2013;98(7):2936\u201343.","journal-title":"J Clin Endocrinol Metab"},{"issue":"10047","key":"1108_CR30","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1016\/S0140-6736(16)00278-6","volume":"388","author":"S De Leo","year":"2016","unstructured":"De Leo S, Lee SY, Braverman LE. Hyperthyroidism. Lancet. 2016;388(10047):906\u201318.","journal-title":"Lancet"},{"issue":"8","key":"1108_CR31","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1111\/j.1524-6175.2006.05180.x","volume":"8","author":"LM Prisant","year":"2006","unstructured":"Prisant LM, Gujral JS, Mulloy AL. Hyperthyroidism: a secondary cause of isolated systolic hypertension. J Clin Hypertens (Greenwich). 2006;8(8):596\u20139.","journal-title":"J Clin Hypertens (Greenwich)"},{"issue":"15","key":"1108_CR32","doi-asserted-by":"crossref","first-page":"1725","DOI":"10.1161\/CIRCULATIONAHA.106.678326","volume":"116","author":"I Klein","year":"2007","unstructured":"Klein I, Danzi S. Thyroid disease and the heart. Circulation. 2007;116(15):1725\u201335.","journal-title":"Circulation"},{"issue":"3","key":"1108_CR33","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1007\/s00268-015-3352-6","volume":"40","author":"S Muthukumar","year":"2016","unstructured":"Muthukumar S, Sadacharan D, Ravikumar K, Mohanapriya G, Hussain Z, Suresh RV. A prospective study on cardiovascular dysfunction in patients with hyperthyroidism and its reversal after surgical cure. World J Surg. 2016;40(3):622\u20138.","journal-title":"World J Surg"},{"issue":"8","key":"1108_CR34","first-page":"e229","volume":"34","author":"JH Suk","year":"2011","unstructured":"Suk JH, Cho KI, Lee SH, Lee HG, Kim SM, Kim TI, et al. Prevalence of echocardiographic criteria for the diagnosis of pulmonary hypertension in patients with Graves\u2019 disease: before and after antithyroid treatment. J Endocrinol Investig. 2011;34(8):e229\u201334.","journal-title":"J Endocrinol Investig"},{"issue":"5","key":"1108_CR35","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1038\/nrendo.2018.18","volume":"14","author":"PN Taylor","year":"2018","unstructured":"Taylor PN, Albrecht D, Scholz A, Gutierrez-Buey G, Lazarus JH, Dayan CM, et al. Global epidemiology of hyperthyroidism and hypothyroidism. Nat Rev Endocrinol. 2018;14(5):301\u201316.","journal-title":"Nat Rev Endocrinol"},{"issue":"3","key":"1108_CR36","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1089\/thy.2018.0320","volume":"29","author":"M Lillevang-Johansen","year":"2019","unstructured":"Lillevang-Johansen M, Abrahamsen B, J\u00f8rgensen HL, Brix TH, Heged\u00fcs L. Duration of hyperthyroidism and lack of sufficient treatment are associated with increased cardiovascular risk. Thyroid. 2019;29(3):332\u201340.","journal-title":"Thyroid"},{"issue":"1","key":"1108_CR37","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1111\/j.1532-5415.1985.tb02854.x","volume":"33","author":"I Saito","year":"1985","unstructured":"Saito I, Ito K, Saruta T. The effect of age on blood pressure in hyperthyroidism. J Am Geriatr Soc. 1985;33(1):19\u201322.","journal-title":"J Am Geriatr Soc"},{"issue":"Suppl 2","key":"1108_CR38","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1007\/s12325-019-01080-8","volume":"36","author":"L Chiovato","year":"2019","unstructured":"Chiovato L, Magri F, Carle A. Hypothyroidism in context: where we\u2019ve been and where we\u2019re going. Adv Ther. 2019;36(Suppl 2):47\u201358.","journal-title":"Adv Ther"},{"issue":"4","key":"1108_CR39","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1067\/mhj.2002.120766","volume":"143","author":"J Dernellis","year":"2002","unstructured":"Dernellis J, Panaretou M. Effects of thyroid replacement therapy on arterial blood pressure in patients with hypertension and hypothyroidism. Am Heart J. 2002;143(4):718\u201324.","journal-title":"Am Heart J"},{"issue":"1","key":"1108_CR40","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1530\/EJE-13-0087","volume":"169","author":"BO Asvold","year":"2013","unstructured":"Asvold BO, Bjoro T, Vatten LJ. Associations of TSH levels within the reference range with future blood pressure and lipid concentrations: 11-year follow-up of the HUNT study. Eur J Endocrinol. 2013;169(1):73\u201382.","journal-title":"Eur J Endocrinol"},{"issue":"2","key":"1108_CR41","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1530\/eje.1.02333","volume":"156","author":"BO Asvold","year":"2007","unstructured":"Asvold BO, et al. The association between TSH within the reference range and serum lipid concentrations in a population-based study. The HUNT Study. Eur J Endocrinol. 2007;156(2):181\u20136.","journal-title":"Eur J Endocrinol"},{"issue":"1","key":"1108_CR42","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1161\/01.HYP.5.1.112","volume":"5","author":"I Saito","year":"1983","unstructured":"Saito I, Ito K, Saruta T. Hypothyroidism as a cause of hypertension. Hypertension. 1983;5(1):112\u20135.","journal-title":"Hypertension"},{"issue":"2","key":"1108_CR43","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1038\/sj.jhh.1000574","volume":"12","author":"AK Fletcher","year":"1998","unstructured":"Fletcher AK, Weetman AP. Hypertension and hypothyroidism. J Hum Hypertens. 1998;12(2):79\u201382.","journal-title":"J Hum Hypertens"},{"issue":"3","key":"1108_CR44","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1210\/jc.2012-4022","volume":"98","author":"MW Yeh","year":"2013","unstructured":"Yeh MW, Ituarte PHG, Zhou HC, Nishimoto S, Amy Liu IL, Harari A, et al. Incidence and prevalence of primary hyperparathyroidism in a racially mixed population. J Clin Endocrinol Metab. 2013;98(3):1122\u20139.","journal-title":"J Clin Endocrinol Metab"},{"key":"1108_CR45","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/j.ijcard.2016.11.080","volume":"227","author":"A Kalla","year":"2017","unstructured":"\u2022\u2022 Kalla A, et al. Primary hyperparathyroidism predicts hypertension: results from the National Inpatient Sample. Int J Cardiol. 2017;227:335\u20137 This study used a patient population from a large national database and showed that after adjusting for age, sex, and cardiac risk factors, the presence of PHPT remained strongly correlated with hypertension.","journal-title":"Int J Cardiol"},{"issue":"5","key":"1108_CR46","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1530\/EJE-09-1067","volume":"162","author":"KM Tordjman","year":"2010","unstructured":"Tordjman KM, Yaron M, Izkhakov E, Osher E, Shenkerman G, Marcus-Perlman Y, et al. Cardiovascular risk factors and arterial rigidity are similar in asymptomatic normocalcemic and hypercalcemic primary hyperparathyroidism. Eur J Endocrinol. 2010;162(5):925\u201333.","journal-title":"Eur J Endocrinol"},{"issue":"3","key":"1108_CR47","doi-asserted-by":"crossref","first-page":"154","DOI":"10.3109\/10641960903254471","volume":"32","author":"CA Feldstein","year":"2010","unstructured":"Feldstein CA, Akopian M, Pietrobelli D, Olivieri A, Garrido D. Long-term effects of parathyroidectomy on hypertension prevalence and circadian blood pressure profile in primary hyperparathyroidism. Clin Exp Hypertens. 2010;32(3):154\u20138.","journal-title":"Clin Exp Hypertens"},{"key":"1108_CR48","doi-asserted-by":"crossref","unstructured":"Letizia C, Ferrari P, Cotesta D, Caliumi C, Cianci R, Cerci S, et al. Ambulatory monitoring of blood pressure (AMBP) in patients with primary hyperparathyroidism. J Hum Hypertens. 2005;19(11):901\u20136.","DOI":"10.1038\/sj.jhh.1001907"},{"issue":"11","key":"1108_CR49","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1056\/NEJMcp1714213","volume":"379","author":"KL Insogna","year":"2018","unstructured":"Insogna KL. Primary hyperparathyroidism. N Engl J Med. 2018;379(11):1050\u20139.","journal-title":"N Engl J Med"},{"issue":"5","key":"1108_CR50","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1016\/j.beem.2018.09.004","volume":"32","author":"BC Silva","year":"2018","unstructured":"Silva BC, Cusano NE, Bilezikian JP. Primary hyperparathyroidism. Best Pract Res Clin Endocrinol Metab. 2018;32(5):593\u2013607.","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"issue":"10116","key":"1108_CR51","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/S0140-6736(17)31430-7","volume":"391","author":"JP Bilezikian","year":"2018","unstructured":"Bilezikian JP, Bandeira L, Khan A, Cusano NE. Hyperparathyroidism. Lancet. 2018;391(10116):168\u201378.","journal-title":"Lancet"},{"issue":"6","key":"1108_CR52","doi-asserted-by":"crossref","first-page":"R297","DOI":"10.1530\/EJE-17-0485","volume":"177","author":"J Pepe","year":"2017","unstructured":"Pepe J, Cipriani C, Sonato C, Raimo O, Biamonte F, Minisola S. Cardiovascular manifestations of primary hyperparathyroidism: a narrative review. Eur J Endocrinol. 2017;177(6):R297\u2013r308.","journal-title":"Eur J Endocrinol"},{"issue":"2","key":"1108_CR53","doi-asserted-by":"crossref","first-page":"49","DOI":"10.14797\/mdcj-13-2-49","volume":"13","author":"SJ Brown","year":"2017","unstructured":"Brown SJ, Ruppe MD, Tabatabai LS. The parathyroid gland and heart disease. Methodist Debakey Cardiovasc J. 2017;13(2):49\u201354.","journal-title":"Methodist Debakey Cardiovasc J"},{"issue":"5","key":"1108_CR54","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1093\/ndt\/12.5.933","volume":"12","author":"D Fliser","year":"1997","unstructured":"Fliser D, Franek E, Fode P, Stefanski A, Schmitt C, Lyons M, et al. Subacute infusion of physiological doses of parathyroid hormone raises blood pressure in humans. Nephrol Dial Transplant. 1997;12(5):933\u20138.","journal-title":"Nephrol Dial Transplant"},{"issue":"4","key":"1108_CR55","first-page":"360","volume":"2","author":"HN Hulter","year":"1986","unstructured":"Hulter HN, Melby JC, Peterson JC, Cooke CR. Chronic continuous PTH infusion results in hypertension in normal subjects. J Clin Hypertens. 1986;2(4):360\u201370.","journal-title":"J Clin Hypertens"},{"issue":"4","key":"1108_CR56","doi-asserted-by":"crossref","first-page":"F1215","DOI":"10.1152\/ajprenal.00406.2006","volume":"292","author":"G Rashid","year":"2007","unstructured":"Rashid G, Bernheim J, Green J, Benchetrit S. Parathyroid hormone stimulates endothelial expression of atherosclerotic parameters through protein kinase pathways. Am J Physiol Ren Physiol. 2007;292(4):F1215\u20138.","journal-title":"Am J Physiol Ren Physiol"},{"key":"1108_CR57","doi-asserted-by":"crossref","first-page":"9582319","DOI":"10.1155\/2018\/9582319","volume":"2018","author":"J Gambardella","year":"2018","unstructured":"Gambardella J, et al. Parathyroid hormone causes endothelial dysfunction by inducing mitochondrial ROS and specific oxidative signal transduction modifications. Oxidative Med Cell Longev. 2018;2018:9582319.","journal-title":"Oxidative Med Cell Longev"},{"issue":"2","key":"1108_CR58","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1016\/S0008-6363(98)00177-1","volume":"40","author":"T Neunteufl","year":"1998","unstructured":"Neunteufl T, Katzenschlager R, Abela C, Kostner K, Niederle B, Weidinger F, et al. Impairment of endothelium-independent vasodilation in patients with hypercalcemia. Cardiovasc Res. 1998;40(2):396\u2013401.","journal-title":"Cardiovasc Res"},{"issue":"2","key":"1108_CR59","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1210\/jc.2014-3949","volume":"100","author":"J Brown","year":"2015","unstructured":"Brown J, de Boer IH, Robinson-Cohen C, Siscovick DS, Kestenbaum B, Allison M, et al. Aldosterone, parathyroid hormone, and the use of renin-angiotensin-aldosterone system inhibitors: the multi-ethnic study of atherosclerosis. J Clin Endocrinol Metab. 2015;100(2):490\u20139.","journal-title":"J Clin Endocrinol Metab"},{"issue":"9","key":"1108_CR60","doi-asserted-by":"crossref","first-page":"1778","DOI":"10.1097\/HJH.0000000000001004","volume":"34","author":"N Verheyen","year":"2016","unstructured":"Verheyen N, Fahrleitner-Pammer A, Pieske B, Meinitzer A, Belyavskiy E, Wetzel J, et al. Parathyroid hormone, aldosterone-to-renin ratio and fibroblast growth factor-23 as determinants of nocturnal blood pressure in primary hyperparathyroidism: the eplerenone in primary hyperparathyroidism trial. J Hypertens. 2016;34(9):1778\u201386.","journal-title":"J Hypertens"},{"issue":"5","key":"1108_CR61","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1159\/000174161","volume":"20","author":"H Schiffl","year":"1997","unstructured":"Schiffl H, Sitter T, Lang SM. Noradrenergic blood pressure dysregulation and cytosolic calcium in primary hyperparathyroidism. Kidney Blood Press Res. 1997;20(5):290\u20136.","journal-title":"Kidney Blood Press Res"},{"issue":"3","key":"1108_CR62","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1161\/01.HYP.4.3.452","volume":"4","author":"ND Vlachakis","year":"1982","unstructured":"Vlachakis ND, Frederics R, Valasquez M, Alexander N, Singer F, Maronde RF. Sympathetic system function and vascular reactivity in hypercalcemic patients. Hypertension. 1982;4(3):452\u20138.","journal-title":"Hypertension"},{"issue":"10","key":"1108_CR63","doi-asserted-by":"crossref","first-page":"3561","DOI":"10.1210\/jc.2014-1413","volume":"99","author":"JP Bilezikian","year":"2014","unstructured":"Bilezikian JP, Brandi ML, Eastell R, Silverberg SJ, Udelsman R, Marcocci C, et al. Guidelines for the management of asymptomatic primary hyperparathyroidism: summary statement from the fourth international workshop. J Clin Endocrinol Metab. 2014;99(10):3561\u20139.","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"1108_CR64","doi-asserted-by":"crossref","first-page":"142","DOI":"10.21037\/gs.2019.10.21","volume":"9","author":"SB Fisher","year":"2020","unstructured":"\u2022\u2022 Fisher SB, Perrier ND. Primary hyperparathyroidism and hypertension. Gland Surg. 2020;9(1):142\u20139 This is the most recent comprehensive review summarizing the available literature regarding the natural history of hypertension and heterogeneous improvement in cardiovascular outcomes after parathyroidectomy.","journal-title":"Gland Surg"},{"issue":"1","key":"1108_CR65","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1007\/s11102-016-0772-8","volume":"20","author":"L Vilar","year":"2017","unstructured":"Vilar L, Vilar CF, Lyra R, Lyra R, Naves LA. Acromegaly: clinical features at diagnosis. Pituitary. 2017;20(1):22\u201332.","journal-title":"Pituitary"},{"issue":"2","key":"1108_CR66","doi-asserted-by":"crossref","first-page":"64","DOI":"10.14797\/mdcj-13-2-64","volume":"13","author":"MD Sharma","year":"2017","unstructured":"Sharma MD, Nguyen AV, Brown S, Robbins RJ. Cardiovascular disease in acromegaly. Methodist Debakey Cardiovasc J. 2017;13(2):64\u20137.","journal-title":"Methodist Debakey Cardiovasc J"},{"issue":"1","key":"1108_CR67","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1007\/s11102-017-0797-7","volume":"20","author":"R Pivonello","year":"2017","unstructured":"Pivonello R, Auriemma RS, Grasso LFS, Pivonello C, Simeoli C, Patalano R, et al. Complications of acromegaly: cardiovascular, respiratory and metabolic comorbidities. Pituitary. 2017;20(1):46\u201362.","journal-title":"Pituitary"},{"issue":"11","key":"1108_CR68","doi-asserted-by":"crossref","first-page":"3933","DOI":"10.1210\/jc.2014-2700","volume":"99","author":"L Katznelson","year":"2014","unstructured":"Katznelson L, Laws ER Jr, Melmed S, Molitch ME, Murad MH, Utz A, et al. Acromegaly: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2014;99(11):3933\u201351.","journal-title":"J Clin Endocrinol Metab"},{"issue":"7","key":"1108_CR69","doi-asserted-by":"crossref","first-page":"2639","DOI":"10.1210\/jc.2008-0299","volume":"93","author":"A Colao","year":"2008","unstructured":"Colao A, Pivonello R, Galderisi M, Cappabianca P, Auriemma RS, Galdiero M, et al. Impact of treating acromegaly first with surgery or somatostatin analogs on cardiomyopathy. J Clin Endocrinol Metab. 2008;93(7):2639\u201346.","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"1108_CR70","doi-asserted-by":"crossref","first-page":"2369","DOI":"10.1210\/jc.2018-00325","volume":"103","author":"B Gonzalez","year":"2018","unstructured":"\u2022\u2022 Gonzalez B, et al. Persistence of diabetes and hypertension after multimodal treatment of acromegaly. J Clin Endocrinol Metab. 2018;103(6):2369\u201375 This study includes a large group of patients with acromegaly and examines the relationship between treatment of acromegaly and improvement in acromegaly-associated diabetes and hypertension.","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"1108_CR71","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1046\/j.1523-1755.2000.00978.x","volume":"57","author":"P Ferrari","year":"2000","unstructured":"Ferrari P, Krozowski Z. Role of the 11beta-hydroxysteroid dehydrogenase type 2 in blood pressure regulation. Kidney Int. 2000;57(4):1374\u201381.","journal-title":"Kidney Int"},{"issue":"9","key":"1108_CR72","doi-asserted-by":"crossref","first-page":"E1234","DOI":"10.1210\/jc.2015-1760","volume":"100","author":"F Pizzolo","year":"2015","unstructured":"Pizzolo F, Friso S, Morandini F, Antoniazzi F, Zaltron C, Udali S, et al. Apparent mineralocorticoid excess by a novel mutation and epigenetic modulation by HSD11B2 promoter methylation. J Clin Endocrinol Metab. 2015;100(9):E1234\u201341.","journal-title":"J Clin Endocrinol Metab"},{"issue":"12","key":"1108_CR73","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1016\/j.bbadis.2009.10.017","volume":"1802","author":"P Ferrari","year":"2010","unstructured":"Ferrari P. The role of 11beta-hydroxysteroid dehydrogenase type 2 in human hypertension. Biochim Biophys Acta. 2010;1802(12):1178\u201387.","journal-title":"Biochim Biophys Acta"},{"issue":"3","key":"1108_CR74","first-page":"335","volume":"16","author":"A Adamidis","year":"2019","unstructured":"\u2022 Adamidis A, et al. Apparent mineralocorticoid excess in the pediatric population: report of a novel pathogenic variant of the 11beta-HSD2 gene and systematic review of the literature. Pediatr Endocrinol Rev. 2019;16(3):335\u201358 This is the most comprehensive review of the clinical presentations and treatment of the pediatric cases of AME to date.","journal-title":"Pediatr Endocrinol Rev"},{"issue":"2","key":"1108_CR75","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1210\/jc.2018-01197","volume":"104","author":"A Tapia-Castillo","year":"2019","unstructured":"Tapia-Castillo A, Baudrand R, Vaidya A, Campino C, Allende F, Valdivia C, et al. Clinical, biochemical, and genetic characteristics of \u201cnonclassic\u201d apparent mineralocorticoid excess syndrome. J Clin Endocrinol Metab. 2019;104(2):595\u2013603.","journal-title":"J Clin Endocrinol Metab"},{"issue":"8563","key":"1108_CR76","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1016\/S0140-6736(87)91014-2","volume":"2","author":"PM Stewart","year":"1987","unstructured":"Stewart PM, Wallace AM, Valentino R, Burt D, Shackleton CH, Edwards CR. Mineralocorticoid activity of liquorice: 11-beta-hydroxysteroid dehydrogenase deficiency comes of age. Lancet. 1987;2(8563):821\u20134.","journal-title":"Lancet"},{"key":"1108_CR77","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.etap.2017.02.021","volume":"52","author":"C Zhou","year":"2017","unstructured":"Zhou C, Ye F, Wu H, Ye H, Chen Q. Recent advances in the study of 11\u03b2-Hydroxysteroid dehydrogenase type 2 (11\u03b2-HSD2) inhibitors. Environ Toxicol Pharmacol. 2017;52:47\u201353.","journal-title":"Environ Toxicol Pharmacol"}],"container-title":["Current Hypertension Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11906-020-01108-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11906-020-01108-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11906-020-01108-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,15]],"date-time":"2024-08-15T23:56:08Z","timestamp":1723766168000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11906-020-01108-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10,20]]},"references-count":77,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2020,11]]}},"alternative-id":["1108"],"URL":"https:\/\/doi.org\/10.1007\/s11906-020-01108-3","relation":{},"ISSN":["1522-6417","1534-3111"],"issn-type":[{"value":"1522-6417","type":"print"},{"value":"1534-3111","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,10,20]]},"assertion":[{"value":"20 October 2020","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"The authors declare no conflicts of interest relevant to this manuscript.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article does not contain any studies with human or animal subjects performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights and Informed Consent"}}],"article-number":"97"}}